Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inogen (INGN) Other financing activities (2013 - 2015)

Inogen (INGN) reported Other financing activities of $870000.0 for Q2 2015, up 9566.67% year-over-year from $9000.0 in Q2 2014, and down 52.15% on a QoQ basis from $1.8 million in Q1 2015.

Inogen (INGN) has 3 years of Other financing activities data on file, last reported at $870000.0 in Q2 2015.

  • Quarterly Other financing activities rose 9566.67% year-over-year to $870000.0 in Q2 2015, while the trailing twelve-month figure through Jun 2015 was -$582000.0 (changed N/A YoY) and the FY2015 annual result came in at -$1.6 million, down 200.0% from the prior year.
  • Other financing activities retreated to $870000.0 in Q2 2015 per INGN's latest filing, from $1.8 million in the prior quarter.
  • Across five years, Other financing activities topped out at $4.9 million in Q1 2014 and bottomed at -$3.3 million in Q4 2014.
  • The 3-year median for Other financing activities is $597000.0 (2013), against an average of $703714.3.
  • The widest annual swing landed in 2014, when Other financing activities tumbled 652.93%; it then jumped 9566.67% in 2015.
  • Tracing INGN's Other financing activities over 3 years: stood at $597000.0 in 2013, then plunged by 652.93% to -$3.3 million in 2014, then surged by 126.36% to $870000.0 in 2015.
  • Per Business Quant, the three latest INGN Other financing activities figures stand at $870000.0 (Q2 2015), $1.8 million (Q1 2015), and -$3.3 million (Q4 2014).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Inogen 165.85 Mn 71.44 Mn 37.86 Mn

Historic Data

Download Data 🔒
DateValue
Jun 30, 2015 870,000.00
Jun 30, 2015 870,000.00
Mar 31, 2015 1.82 Mn
Mar 31, 2015 1.82 Mn
Dec 31, 2014 -3.30 Mn
Dec 31, 2014 -3.30 Mn
Sep 30, 2014 31,000.00
Sep 30, 2014 31,000.00
Jun 30, 2014 9,000.00
Jun 30, 2014 9,000.00
Mar 31, 2014 4.90 Mn
Mar 31, 2014 4.90 Mn
Dec 31, 2013 597,000.00
Dec 31, 2013 597,000.00